Sitagliptin
Medicare prescription drug cost, prescriptions and prescribers, 2024
$3.3M
Medicare cost, 2024
$3.3M
Medicare cost, 2024
Medicare drug plans spent $3.3 million on Sitagliptin in 2024, for 10,245 prescriptions and refills filled by 6,175 patients. It was first approved in 2023. California accounts for the most spending ($1.5 million, 44% of the total).
Medicare cost, 2024
$3.3M
Prescriptions
10K
$324.62 per claim
Patients
6,175
3,629 prescribers
Total spending, 2024
$3.3M
$538.59 per patient
Questions and answers
How much does Medicare spend on Sitagliptin?
Medicare prescription drug plans paid $3.3M for Sitagliptin in 2024, for 10,245 prescriptions and refills to 6,175 patients. The average cost per claim was $324.62.
Which state spends the most on Sitagliptin?
California had the highest Medicare cost for Sitagliptin in 2024: $1.5M for 5,568 claims, followed by New York ($429K).
Who prescribes Sitagliptin the most?
Ian Kirkpatrick, family practice in Talihina, OK, had the highest Medicare cost for Sitagliptin in 2024: 85 claims costing $42K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Sitagliptin, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Ian Kirkpatrick Talihina, OK | Family Practice | 85 | 18 | $42K |
| Rafael Junco Hialeah, FL | Family Practice | 48 | 17 | $30K |
| Maurin Jimenez Miami, FL | Family Practice | 42 | 22 | $26K |
| Byagari Narayana Brooklyn, NY | Internal Medicine | 28 | Under 11 | $22K |
| Michael R Mason Ada, OK | Family Practice | 38 | Under 11 | $19K |
| Maribel Colon-Santiago Lawton, OK | Family Practice | 66 | 18 | $13K |
| Katia Fajardo Martinez Hialeah, FL | General Practice | 18 | Under 11 | $12K |
| Eric S Lee Tishomingo, OK | Family Practice | 23 | Under 11 | $11K |
| Andrea D Coley Heavener, OK | Nurse Practitioner | 22 | Under 11 | $11K |
| Frank C Alvarez Li Hialeah, FL | General Practice | 17 | Under 11 | $11K |
| Mohammad A Khan Wichita Falls, TX | Family Practice | 41 | 13 | $9,933 |
| Morgan N Dickerson Shiprock, NM | Family Practice | 24 | Under 11 | $8,733 |
| Jin Y Jeon Panorama City, CA | Internal Medicine | 34 | 20 | $8,013 |
| Andres Bustamante Chula Vista, CA | Internal Medicine | 37 | 23 | $7,833 |
| Jose J Gomez Idabel, OK | Family Practice | 15 | Under 11 | $7,316 |
| Christie A Leal Carnegie, OK | Family Practice | 24 | Under 11 | $6,703 |
| Max H Brummett Harbor City, CA | Physician Assistant | 23 | 18 | $6,500 |
| Peter B Jalbuena Burbank, CA | Internal Medicine | 24 | 17 | $6,373 |
| Olen L Jestis II Durant, OK | Family Practice | 15 | Under 11 | $6,332 |
| William J Hayes Fort Smith, AR | Family Practice | 13 | Under 11 | $6,288 |
| Gem M Bartsch Scottsdale, AZ | Nurse Practitioner | 12 | Under 11 | $6,135 |
| Viviana Petru Bronx, NY | Internal Medicine | 20 | 13 | $6,132 |
| Jacqueline Fernandez Homestead, FL | Clinic or Group Practice | 13 | Under 11 | $6,101 |
| Patricia J Redhage Heavener, OK | Nurse Practitioner | 12 | Under 11 | $5,670 |
| Lilian B Ruano Ceballos Miami, FL | Nurse Practitioner | 12 | Under 11 | $5,632 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2024 | 3,629 | 10,245 | 6,175 | $3.3M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Zydus Pharmaceu | 10,247 | $3.3M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 30
- RxNorm concept IDs
- 2709603, 2709608, 2709612, 665033, 665038
- Application numbers
- ANDA202327, ANDA202425, NDA211566
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 72,500 side-effect reports named sitagliptin (reports from 2006 on). 46,832 of them (64.6%) were serious, 6,841 named a death and 25,279 named a hospital stay. The reactions named most often were blood glucose increased, nausea and diarrhoea. 14,206 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
72,500
2,807 in 2025 (-1.6% from 2024)
Serious
64.6%
46,832 reports
Deaths named
6,841
9.4% of reports
Hospital stays
25,279
34.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Sitagliptin?
72,500 reports from 2006 through September 2026 named sitagliptin. 46,832 of them (64.6%) were serious, 6,841 named a death and 25,279 named a hospital stay.
What are the most reported side effects of Sitagliptin?
4,522 reports named blood glucose increased, the reaction named most often, followed by nausea (3,969) and diarrhoea (3,635). In the last 5 years the reaction named most often was product dose omission issue (1,066 reports). A report can name several reactions.
How many side-effect reports named Sitagliptin in 2025?
2,807 reports were received in 2025 (-1.6% from 2024). 2026 so far: 2,035 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Sitagliptin caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Sitagliptin caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with sitagliptin: Januvia
- Makers on the stock market:
MRK·MRK drug pipeline - Drug approvals (4 approvals on file for sitagliptin) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (sitagliptin) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.